NetworkNewsBreaks – Endonovo Therapeutics Inc. (
Post# of 416
(Total Views: 968)
Posted On: 08/14/2019 4:17:01 PM
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Posts Q2 2019 Financial Results
Endonovo Therapeutics (OTCQB: ENDV) on Tuesday posted the company’s financial and operating results for the second quarter. The company reported revenues for the three months ended June 30, 2019 of $62,729, a sharp increase compared to $12,854 for the same period last year. Gross profits for the second quarter were $33,156, as compared to $12,304 for the same period last year. Endonovo also provided an update on the PEMF assets it acquired from Rio Grande Neurosciences for $4.5 million in December 2017. “I am pleased to announce we have executed the business plan and strategy we implemented after acquiring the PEMF assets and technology in December 2017, and I am additionally excited to announce the results we attained throughout the first six months of this year. Our sales network in 2018 included two distributors and several independent sales representatives throughout the United States, which began our sales and marketing efforts for SofPulse(R), ultimately leading to our revenues. Throughout 2019 we expanded our team of independent sales representatives, began our marketing launch into the U.S. hospitals and we are focusing on expanding nationally,” Endonovo Therapeutics CEO Alan Collier stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV) on Tuesday posted the company’s financial and operating results for the second quarter. The company reported revenues for the three months ended June 30, 2019 of $62,729, a sharp increase compared to $12,854 for the same period last year. Gross profits for the second quarter were $33,156, as compared to $12,304 for the same period last year. Endonovo also provided an update on the PEMF assets it acquired from Rio Grande Neurosciences for $4.5 million in December 2017. “I am pleased to announce we have executed the business plan and strategy we implemented after acquiring the PEMF assets and technology in December 2017, and I am additionally excited to announce the results we attained throughout the first six months of this year. Our sales network in 2018 included two distributors and several independent sales representatives throughout the United States, which began our sales and marketing efforts for SofPulse(R), ultimately leading to our revenues. Throughout 2019 we expanded our team of independent sales representatives, began our marketing launch into the U.S. hospitals and we are focusing on expanding nationally,” Endonovo Therapeutics CEO Alan Collier stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Scroll down for more posts ▼